Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Código QR

Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma

Guardado en:

Detalles Bibliográficos
Autores principales:	Lieve Brochez, Annabel Meireson, Inès Chevolet, Nora Sundahl, Piet Ost, Vibeke Kruse
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/cccf2c3139cb40d482a19d5c3be95eb4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’
por: Nicolas Jacquelot, et al.
Publicado: (2018)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: A. Flaus, et al.
Publicado: (2021)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Dinoop Ravindran Menon, et al.
Publicado: (2021)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Sarah J. Dart, et al.
Publicado: (2021)

miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma
por: Mai-Huong Thi Nguyen, et al.
Publicado: (2021)

LYMPHOCYTE PHENOTYPE IN PATIENTS WITH SKIN MELANOMA AFTER IMMUNOTHERAPY OF ACTIVATED LYMPHOCYTES
por: E. V. Abakushina, et al.
Publicado: (2015)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Marisa Schmitt, et al.
Publicado: (2021)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li SY, et al.
Publicado: (2013)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Clemens Hinterleitner, et al.
Publicado: (2021)

Dermoscopic Predictors of Tumor Thickness in Cutaneous Melanoma: A Retrospective Analysis of 245 Melanomas
por: Enrique Rodríguez-Lomba, et al.
Publicado: (2021)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kensuke Kojima, et al.
Publicado: (2021)

The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy
por: Gui-Zhen Wang, et al.
Publicado: (2019)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021)

Pattern Recognition Receptors (PRRs) in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma
por: Qihang Zhao, et al.
Publicado: (2021)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: N. Jacquelot, et al.
Publicado: (2017)

Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
por: Hongji Zhang, et al.
Publicado: (2021)

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
por: Heidi M. Haikala, et al.
Publicado: (2019)

Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
por: Naixue Yang, et al.
Publicado: (2021)

Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
por: A. V. Chetveryakov, et al.
Publicado: (2021)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021)

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
por: Wantong Song, et al.
Publicado: (2018)

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
por: Douglas B. Johnson, et al.
Publicado: (2016)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy
por: Noha M. Hammad, et al.
Publicado: (2021)

Mutation load estimation model as a predictor of the response to cancer immunotherapy
por: Guan-Yi Lyu, et al.
Publicado: (2018)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Florie Bertrand, et al.
Publicado: (2017)

Immunotherapy in Breast Cancer: When, How, and What Challenges?
por: Beatriz Henriques, et al.
Publicado: (2021)

Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
por: Náthali Felícia Mineiro Dos Santos Garrett, et al.
Publicado: (2021)

Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy
por: Liangrong Shi, et al.
Publicado: (2019)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Naiqing Ding, et al.
Publicado: (2019)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
por: Jing Zhou, et al.
Publicado: (2022)

High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis
por: Yoonhyuk Jang, et al.
Publicado: (2018)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Thomas F Gajewski, et al.
Publicado: (2021)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Hui Tian, et al.
Publicado: (2021)

Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse
por: Roxana Khazen, et al.
Publicado: (2016)

Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Marije J. Voskamp, et al.
Publicado: (2021)

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
por: Heidi M. Haikala, et al.
Publicado: (2019)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Sjoerd H van der Burg, et al.
Publicado: (2021)

Predictors of occult lymph node metastasis in cutaneous head and neck melanoma
por: Jonathan S. Ni, et al.
Publicado: (2019)

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Antoni Ribas, et al.
Publicado: (2020)